MX2023011059A - Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion. - Google Patents

Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.

Info

Publication number
MX2023011059A
MX2023011059A MX2023011059A MX2023011059A MX2023011059A MX 2023011059 A MX2023011059 A MX 2023011059A MX 2023011059 A MX2023011059 A MX 2023011059A MX 2023011059 A MX2023011059 A MX 2023011059A MX 2023011059 A MX2023011059 A MX 2023011059A
Authority
MX
Mexico
Prior art keywords
long
growth hormone
treating inflammation
induced diseases
acting growth
Prior art date
Application number
MX2023011059A
Other languages
English (en)
Inventor
Kennett Sprogøe
Yang Yang-Malten
Mads Jens Kjelgaard-Hansen
Nora Elisabeth Zois
Poulsen Thomas Tuxen
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of MX2023011059A publication Critical patent/MX2023011059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención es concerniente con una hormona del crecimiento (GH) de acción prolongada para uso en el tratamiento de una enfermedad inducida por inflamación.
MX2023011059A 2021-04-01 2022-03-31 Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion. MX2023011059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166699 2021-04-01
PCT/EP2022/058584 WO2022207798A1 (en) 2021-04-01 2022-03-31 Use of long-acting growth hormone for treating inflammation-induced diseases

Publications (1)

Publication Number Publication Date
MX2023011059A true MX2023011059A (es) 2023-09-29

Family

ID=75362497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011059A MX2023011059A (es) 2021-04-01 2022-03-31 Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.

Country Status (10)

Country Link
EP (1) EP4314035A1 (es)
JP (1) JP2024514095A (es)
KR (1) KR20230164709A (es)
CN (1) CN117396497A (es)
AU (1) AU2022246997A1 (es)
BR (1) BR112023018802A2 (es)
CA (1) CA3212417A1 (es)
IL (1) IL307192A (es)
MX (1) MX2023011059A (es)
WO (1) WO2022207798A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
DK1620118T3 (da) 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
US8906847B2 (en) 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
JP2011520983A (ja) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
EA024755B1 (ru) 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Биосинтетические нерегулярные спиральные полипептиды пролина/аланина и их применения
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
US20140296257A1 (en) 2011-08-12 2014-10-02 Ascendis Pharma A/S High-Loading Water-Soluable Carrier-Linked Prodrugs
KR102226702B1 (ko) 2011-09-07 2021-03-11 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
CA2968282A1 (en) 2014-11-18 2016-05-26 Thomas Kurpiers Polymeric hgh prodrugs
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3856257A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
SG11202101971XA (en) 2018-09-26 2021-03-30 Ascendis Pharma As Novel hydrogel conjugates
BR112021020023A2 (pt) 2019-04-05 2021-12-07 Prolynx Llc Ligantes de conjugação melhorados
WO2021030196A1 (en) 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release

Also Published As

Publication number Publication date
IL307192A (en) 2023-11-01
BR112023018802A2 (pt) 2023-10-31
AU2022246997A1 (en) 2023-09-28
EP4314035A1 (en) 2024-02-07
WO2022207798A1 (en) 2022-10-06
KR20230164709A (ko) 2023-12-04
CA3212417A1 (en) 2022-10-06
CN117396497A (zh) 2024-01-12
JP2024514095A (ja) 2024-03-28
AU2022246997A9 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MXPA04004552A (es) Compuestos tipo indolizina sustituida y metodos de uso.
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
SI1042293T1 (sl) Substituirane piridinske in piridazinske spojine in njihova farmacevtska uporaba
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
MX2023011059A (es) Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021010286A (es) Formas de dosificacion de la hormona del crecimiento de accion prolongada con eficacia superior a la somatropina diaria.
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
PH12020551529A1 (en) Fungicidal fertilizer composition comprising potassium phosphite and t-poly-glutamic acid
WO2020128614A8 (en) Method for treating interstital lung disease
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
MX2021001985A (es) Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
CR20200649A (es) Agosnistas de tlr7
AP2004003177A0 (en) Composition and its therapeutic use
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
MX2021009045A (es) Moduladores de transporte nuclear que contienen acrilo y uso de los mismos.
MX2021001710A (es) Compuestos de fluoro ?-carbolina.